Gritstone Oncology Inc.

Available to platforms
R StocksTrader

Gritstone Oncology Inc. (GRTS) on the NASDAQ Exchange

Company overview

Gritstone Oncology Inc. is a publicly listed company from USA with shares traded on NASDAQ under the ticker GRTS. This page provides a live view of market pricing and an interactive chart to follow short and long-term moves without manual refresh. The latest streaming quotes for GRTS are bid 0.02 USD and ask 0.04 USD.

Use the chart to review recent momentum, identify key price areas, and track how Gritstone Oncology Inc. is performing relative to your portfolio in 2025. If you are researching the instrument for trading or investing, add GRTS to your watchlist in R StocksTrader and compare it with other US and European shares, indices, and metals.

Key facts

  • Exchange: NASDAQ
  • Company: Gritstone Oncology Inc.
  • Ticker: GRTS
  • Country: USA
  • Bid0.02 USD
  • Ask0.04 USD
  • Quotes: real-time, auto-updated

Risk

Risk Warning: Past performance of GRTS does not predict future returns.

FAQ

Open a trading account at RoboForex, decide on the number of assets to buy, and then place an order for Gritstone Oncology Inc. (GRTS) in R StocksTrader. Create and verify your profile, fund the account, search for GRTS, and choose the instrument type available to you. Add GRTS to your Watchlist to track moves and manage open positions throughout 2025.

GRTS trades on NASDAQ and is issued by Gritstone Oncology Inc.. This page provides a live chart and continuously updated price data for the 2025 year so that you can follow intraday swings and longer trends. Before starting trading and placing orders, review trading hours, typical spreads, and fees in the terminal to make sure conditions for GRTS match your plan.

Quotes update automatically in real time. Current levels for GRTS are bid 0.02 USD and ask 0.04 USD. The spread is the difference between ask and bid and affects your effective entry and exit. Track GRTS in R StocksTrader and adjust your approach as market conditions change in 2025.